Optimizing Administration of Zongertinib in HER2-Positive NSCLC

Joshua K. Sabari, MD, discusses dosing, administration, and optimal patient management when using zongertinib to treat patients with HER2 mutation–positive non–small cell lung cancer. He describes the standard weight-based dosing of the treatment as well as the adverse events to monitor early on to ensure optimal administration of zongertinib.